3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
8
Glioma
4
Multiple Myeloma
3
Thyroid Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Astrocytoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Interventions
ruxolitinib
13
Cyclophosphamide
5
Tacrolimus
4
fludarabine phosphate
3
Whole-Body Irradiation
3
Stem Cell Transplantation
3
Specimen Handling
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Cyclosporine
3
fludarabine
2
fedratinib
2
Sirolimus
2
Injections
2
Busulfan
2
Biopsy
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
veliparib
1
umbralisib
1
thymoglobulin
1
selinexor
1
reparixin
1
piperine
1
pegylated granulocyte colony-stimulating factor
1
navitoclax
1
luspatercept
1
letermovir
1
itacitinib
1
iadademstat
1
demethoxycurcumin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
dabrafenib
×
90 days
×
Clear all
No trials found.